Teva Inks $450m Deals Over US Kickback Claims, Including For Generic Price-Fixing
Eight-Figure Payment In Addition To $225m Criminal Penalty Imposed On Teva Last Year
Executive Summary
Teva has resolved a pair of civil US Department of Justice lawsuits accusing the firm of violating the US Anti-Kickback Statute and the False Claims Act through its alleged conduct conspiring to fix the price of three generic drugs and for allegedly paying Medicare patients’ copays for its multiple sclerosis brand Copaxone.